The offshoring of clinical trials via clinical research organisations has become a common practice among multinational pharmaceutical countries. A number of concerns have been raised about the ethical variability that this has engendered with differing guidelines and regulations found in different countries. There are also concerns about the relevance of clinical research to the populations from where research subjects are recruited as well as about benefit sharing and ethical oversight.